This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, Y. Articles by Kulesz-Martin, M. F. Search for Related Content PubMed PubMed Citation Articles by Liu, Y. Articles by Kulesz-Martin, M. F.

Functional Quantification of DNA-binding Proteins p53 and Estrogen Receptor in Cells and Tumor Tissues by DNA Affinity Immunoblotting¹

Department of Dermatology and Oregon Cancer Center, Oregon Health Sciences University, Portland, Oregon 97201 [Y. L., M. F. K-M.], and Departments of Pharmacology and Therapeutics and of Experimental Pathology, Roswell Park Cancer Institute, Buffalo, New York 14263 [H. A.]

Functional assays of proteins can monitor the consequences of defects attributable to posttranslational activating or inhibitory events as well as to genetic mutations. Such assays promise to permit evaluation of cooperating oncogenic or tumor suppressor pathways in cells and tumors. As a step toward realizing this promise, we designed the DNA affinity immunoblotting (DAI) method to measure the activities of multiple sequence-specific DNA-binding proteins simultaneously [initially p53 and estrogen receptor (ER)] in lysates of cells or frozen tumor tissues. DAI is a novel application of biotin/streptavidin affinity chromatography and immunoblotting. The p53 and ER proteins in cell or tissue lysates were bound to biotinylated, specific DNA probes, retrieved using a streptavidin-conjugated matrix, and then quantified in parallel with total protein by immunoblotting. The assay results were reproducible and specifically correlated with the known functional status of p53 in mouse and human cells of known p53 genotype, including those with low levels of p53 protein. ER immunohistochemistry of human breast samples, which is highly correlated with functional status and prognosis in human breast cancer, was also highly correlated with DNA binding activity results by DAI. In contrast, the p53 protein in cells is frequently expressed but inactive, potentially accounting for the lack of strict correlation of p53 immunohistochemical or mutational status with tumor response to chemotherapy. DAI offers a new means of molecular profiling and monitoring of p53 and other DNA-binding protein activities in cells and tumors. DAI has applications in the detection and identification of covalently modified forms of DNA-binding proteins and in the identification of their interacting proteins in complex with DNA.

This article has been cited by other articles:

				M. R. Lopez-Huertas, S. Callejas, D. Abia, E. Mateos, A. Dopazo, J. Alcami, and M. Coiras Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon Nucleic Acids Res., February 5, 2010; (2010) gkq037v1. [Abstract] [Full Text] [PDF]

				J. Zhang, M. A. Warren, S. F. Shoemaker, and M. M. Ip NF{kappa}B1/p50 Is Not Required for Tumor Necrosis Factor-Stimulated Growth of Primary Mammary Epithelial Cells: Implications for NF{kappa}B2/p52 and RelB Endocrinology, January 1, 2007; 148(1): 268 - 278. [Abstract] [Full Text] [PDF]

				S. Tsuzuki, K. Kitajima, T. Nakano, A. Glasow, A. Zelent, and T. Enver Cross Talk between Retinoic Acid Signaling and Transcription Factor GATA-2 Mol. Cell. Biol., August 1, 2004; 24(15): 6824 - 6836. [Abstract] [Full Text] [PDF]

				H. Zhang, H. Zhang, L. Lee, and M. M. Ip The Liver-Enriched Inhibitory Protein Isoform of CCAAT/Enhancer-Binding Protein {beta}, But Not Nuclear Factor-{kappa}B, Mediates the Transcriptional Inhibition of {beta}-Casein by Tumor Necrosis Factor-{alpha} Endocrinology, June 1, 2004; 145(6): 2833 - 2844. [Abstract] [Full Text] [PDF]

				C. D. Knights, Y. Liu, E. Appella, and M. Kulesz-Martin Defective p53 Post-translational Modification Required for Wild Type p53 Inactivation in Malignant Epithelial Cells with mdm2 Gene Amplification J. Biol. Chem., December 26, 2003; 278(52): 52890 - 52900. [Abstract] [Full Text] [PDF]

				C. Geserick, H.-A. Meyer, K. Barbulescu, and B. Haendler Differential Modulation of Androgen Receptor Action by Deoxyribonucleic Acid Response Elements Mol. Endocrinol., September 1, 2003; 17(9): 1738 - 1750. [Abstract] [Full Text] [PDF]

				S. X. Zeng, Y. Jin, D. T. Kuninger, P. Rotwein, and H. Lu The Acetylase Activity of p300 Is Dispensable for MDM2 Stabilization J. Biol. Chem., February 21, 2003; 278(9): 7453 - 7458. [Abstract] [Full Text] [PDF]

				Y. Jin, S. X. Zeng, M.-S. Dai, X.-J. Yang, and H. Lu MDM2 Inhibits PCAF (p300/CREB-binding Protein-associated Factor)-mediated p53 Acetylation J. Biol. Chem., August 16, 2002; 277(34): 30838 - 30843. [Abstract] [Full Text] [PDF]

				S. Tsuzuki and T. Enver Interactions of GATA-2 with the promyelocytic leukemia zinc finger (PLZF) protein, its homologue FAZF, and the t(11;17)-generated PLZF-retinoic acid receptor alpha oncoprotein Blood, May 1, 2002; 99(9): 3404 - 3410. [Abstract] [Full Text] [PDF]